Skip to content

An human clinical study to check the efficacy of an herbal toothpaste in reducing Gingivitis (a tooth-related condition) in Diabetic population.

An open-label single arm human clinical study to investigate the efficacy of an herbal toothpaste (GHT - 12) in reducing Gingivitis (early stage of Periodontal disease) in Diabetic population.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052497
Enrollment
72
Registered
2023-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: GHT-12: Herbal toothpaste with herbal actives (Xylitol and combination of essential oils and extracts) for brushing twice daily. Control Intervention1: Not Applicable.: Not Applicable.

Sponsors

Amway Global Services India Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Presence of gingivitis 2. All subjects fulfilled at least one or more of the clinical criteria 3. Controlled diabetes mellitus 4. Having at least 20 teeth 5. Agreement to participate in the study 6. Able and willing to follow all study related instructions. 7. Must be willing to give written informed consent and comply with the study procedures. 8. Subjectâ??s complete blood count parameters to be within clinically acceptable range by Investigator. 9. No history of periodontal therapy or previous use of antibiotics or anti-inflammatory medication within the preceding 1 month

Exclusion criteria

Exclusion criteria: 1. History of hypersensitivity reaction 2. Smoking/ consuming Betel nut/Pan/ Beeda 3. Systemic diseases (Kidney, liver or rheumatologic diseases) 4. To have a pocket depth of more than 5mm 5. Consumption of antibiotics, corticosteroids or nonsteroidal anti-inflammatory drugs in the past 1month and during the study period 6. Subjects with known allergies to the constituents of the formulation 7. Subjects with uncontrolled Hypertension, endocrinal, metabolic disorders excluding diabetes mellitus, underlying heart conditions and other uncontrolled systemic disorders 8. Pregnant and lactating females 9. Subjects undergoing orthodontic treatment 10. Any condition that in the opinion of the investigator does not justify the subjectâ??s inclusion for the study.

Design outcomes

Primary

MeasureTime frame
To assess change from baseline for Modified Gingival Index.Timepoint: Day 1, Day 10, Day 20, Day 30.

Secondary

MeasureTime frame
1. To assess change from baseline for Plaque Index 2. To assess change from baseline for Bleeding Index 3. To assess change from baseline for Pocket depth 4. To assess change from baseline for S. mutans count 5. To assess change from baseline in reduction of malodour 6. To assess change from baseline in hypersensitivity 7. To assess change from baseline in teeth whiteness 8. To assess change from baseline in extrinsic stains 9. Subjective perception or Subject satisfaction 10. Product Acceptability QuestionnaireTimepoint: Day 1, Day 10, Day 20, Day 30.

Countries

India

Contacts

Public ContactMr Siddesh Shetty

KLE Societys Institute of Dental Sciences

prabhu.ash@gmail.com9845011615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026